BIOGEN INC (IDP.DE) Stock Fundamental Analysis

FRA:IDP • US09062X1037

161.1 EUR
-0.7 (-0.43%)
Last: Feb 11, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to IDP. IDP was compared to 81 industry peers in the Biotechnology industry. IDP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IDP has a bad growth rate and is valued cheaply. This makes IDP very considerable for value investing!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year IDP was profitable.
  • In the past year IDP had a positive cash flow from operations.
  • Of the past 5 years IDP 4 years were profitable.
  • Of the past 5 years IDP 4 years had a positive operating cash flow.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

  • With an excellent Return On Assets value of 5.51%, IDP belongs to the best of the industry, outperforming 81.48% of the companies in the same industry.
  • IDP has a Return On Equity of 8.84%. This is amongst the best in the industry. IDP outperforms 81.48% of its industry peers.
  • IDP has a Return On Invested Capital of 9.70%. This is amongst the best in the industry. IDP outperforms 86.42% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IDP is in line with the industry average of 12.03%.
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROIC 9.7%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • IDP has a Profit Margin of 15.98%. This is amongst the best in the industry. IDP outperforms 82.72% of its industry peers.
  • IDP's Profit Margin has declined in the last couple of years.
  • IDP has a better Operating Margin (28.50%) than 87.65% of its industry peers.
  • In the last couple of years the Operating Margin of IDP has declined.
  • The Gross Margin of IDP (75.24%) is better than 62.96% of its industry peers.
  • In the last couple of years the Gross Margin of IDP has declined.
Industry RankSector Rank
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IDP is destroying value.
  • There is no outstanding debt for IDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • IDP has an Altman-Z score of 3.42. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of IDP (3.42) is better than 70.37% of its industry peers.
  • IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
  • IDP has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. IDP outperforms 82.72% of its industry peers.
  • IDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of IDP (0.35) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Altman-Z 3.42
ROIC/WACC0.81
WACC11.95%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.72, IDP is in line with its industry, outperforming 56.79% of the companies in the same industry.
  • A Quick Ratio of 2.04 indicates that IDP has no problem at all paying its short term obligations.
  • IDP has a Quick ratio (2.04) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.04
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The earnings per share for IDP have decreased by -7.16% in the last year.
  • IDP shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.17% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 1.58% on average per year.
  • IDP is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.22% yearly.
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y1.58%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-1.22%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 12.54 indicates a correct valuation of IDP.
  • 95.06% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of IDP to the average of the S&P500 Index (28.18), we can say IDP is valued rather cheaply.
  • The Price/Forward Earnings ratio is 12.60, which indicates a correct valuation of IDP.
  • IDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 97.53% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.01, IDP is valued rather cheaply.
Industry RankSector Rank
PE 12.54
Fwd PE 12.6
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 90.12% of the companies in the same industry are more expensive than IDP, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 95.06% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.43
EV/EBITDA 8.36
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y3.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIOGEN INC

FRA:IDP (2/11/2026, 7:00:00 PM)

161.1

-0.7 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners96.04%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap23.63B
Revenue(TTM)N/A
Net Income(TTM)1.61B
Analysts73.33
Price Target165.61 (2.8%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)6.55%
PT rev (3m)10.11%
EPS NQ rev (1m)2%
EPS NQ rev (3m)1.28%
EPS NY rev (1m)0.25%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE 12.54
Fwd PE 12.6
P/S 2.79
P/FCF 12.43
P/OCF 11.46
P/B 1.54
P/tB 11.79
EV/EBITDA 8.36
EPS(TTM)12.85
EY7.98%
EPS(NY)12.78
Fwd EY7.94%
FCF(TTM)12.96
FCFY8.04%
OCF(TTM)14.06
OCFY8.72%
SpS57.66
BVpS104.3
TBVpS13.66
PEG (NY)N/A
PEG (5Y)N/A
Graham Number173.65
Profitability
Industry RankSector Rank
ROA 5.51%
ROE 8.84%
ROCE 11.07%
ROIC 9.7%
ROICexc 11.44%
ROICexgc 40.96%
OM 28.5%
PM (TTM) 15.98%
GM 75.24%
FCFM 22.48%
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.15%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.78
Debt/EBITDA 1.73
Cap/Depr 25.04%
Cap/Sales 1.9%
Interest Coverage 250
Cash Conversion 67.56%
Profit Quality 140.63%
Current Ratio 2.72
Quick Ratio 2.04
Altman-Z 3.42
F-Score5
WACC11.95%
ROIC/WACC0.81
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y-0.5%
EPS Next 2Y2.48%
EPS Next 3Y3.07%
EPS Next 5Y1.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-7.14%
Revenue Next Year-5.09%
Revenue Next 2Y-2.76%
Revenue Next 3Y-1.56%
Revenue Next 5Y-1.22%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year3.51%
EBIT Next 3Y0.64%
EBIT Next 5Y1.51%
FCF growth 1Y120.5%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.46%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%

BIOGEN INC / IDP.DE FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


What is the profitability of IDP stock?

BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.


What is the financial health of BIOGEN INC (IDP.DE) stock?

The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.


What is the expected EPS growth for BIOGEN INC (IDP.DE) stock?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -0.5% in the next year.